Document is current
Any future updates will be listed below
-
Authors
McLaren, James
Gao, Xuan http://orcid.org/0009-0003-0562-4170
Ghouri, Nazim http://orcid.org/0000-0002-8263-2591
Freeman, Dilys J. http://orcid.org/0000-0002-6078-5271
Richardson, Janice http://orcid.org/0000-0002-8207-0891
Sattar, Naveed http://orcid.org/0000-0002-1604-2593
Gill, Jason M. R. http://orcid.org/0000-0003-3615-0986
-
Funding
Funding for this research was provided by:
European Federation of Pharmaceutical Industries Associations (EFPIA)-Innovative Medicines Initiative (IMI) Joint Undertaking-European Medical Information Framework (EMIF)
- License Information
-
More Information
Article History
Received: 24 July 2023
Accepted: 9 July 2024
First Online: 16 August 2024
Competing interests
: N.S. reports consulting and/or speaker fees from Abbott Laboratories, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics and Sanofi; and institutional grant support from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics outside the submitted work. The other authors declare no competing interests.
